About FDA

NCTR Research Highlights

 Red envelope icon for GovdeliveryGet e-mail updates when this information changes.

Current Highlight from October 14, 2016

Sex Differences in Doxorubicin-Induced Cardiotoxicity   

Scientists from NCTR, the National Cancer Institute, the Arkansas Heart Hospital, and Korea University have demonstrated an increased susceptibility to doxorubicin (DOX)-induced cardiac toxicity in adult male mice as compared to adult female mice, reflecting the differential toxicity noted in male and female cancer patients treated with DOX.  Male mice exhibited greater myocardial damage than their female counterparts as evidenced by increases in cardiac troponin T levels in plasma, the development of cytoplasmic vacuolization in cardiomyocytes, and increases in apoptosis and DNA damage in the myocardium, particularly in the left atrium.  This new mouse model has the potential to address biological mechanisms of DOX-induced cardiac injury and to identify sex-specific early biomarkers of DOX-induced cardiotoxicity.  This may open avenues for ameliorating the toxicity of this highly effective anti-cancer drug.  This publication is now available online at Toxicology and Applied Pharmacologydisclaimer icon.

 For more information, please contact Varsha Desai, Ph.D., Division of Systems Biology, FDA/NCTR.




Contact FDA

National Center for Toxicological Research

Food and Drug Administration

3900 NCTR Road

Jefferson, AR 72079

Page Last Updated: 10/21/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English